Advertisement
UK markets close in 1 hour 10 minutes
  • FTSE 100

    8,341.47
    -28.86 (-0.34%)
     
  • FTSE 250

    20,658.25
    -51.82 (-0.25%)
     
  • AIM

    803.04
    -0.83 (-0.10%)
     
  • GBP/EUR

    1.1734
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.2712
    -0.0008 (-0.06%)
     
  • Bitcoin GBP

    53,567.03
    -1,352.91 (-2.46%)
     
  • CMC Crypto 200

    1,472.19
    -30.48 (-2.03%)
     
  • S&P 500

    5,311.12
    +4.11 (+0.08%)
     
  • DOW

    39,426.88
    -244.16 (-0.62%)
     
  • CRUDE OIL

    78.17
    +0.60 (+0.77%)
     
  • GOLD FUTURES

    2,357.10
    -35.80 (-1.50%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • HANG SENG

    18,868.71
    -326.89 (-1.70%)
     
  • DAX

    18,662.19
    -18.01 (-0.10%)
     
  • CAC 40

    8,101.04
    +8.93 (+0.11%)
     

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

Inozyme Pharma Inc.
Inozyme Pharma Inc.

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

ADVERTISEMENT

For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedInX, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com